C. Sachs

Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers

W. Cheung, K. Thudium, E. Bouillaud, 2015, Clinical pharmacology : advances and applications.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C Yao, N. Fazio, M. Pavel, 2016, The Lancet.

Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.

S. Libutti, James C Yao, N. Fazio, 2016 .

Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study

Y. Shimada, James C Yao, N. Fazio, 2016 .

134ORADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

Y. Shimada, James C Yao, S. Singh, 2015 .

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Y. Shimada, James C Yao, N. Fazio, 2015 .

Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3)

M. Shah, James C Yao, T. Hobday, 2011 .

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

J. Esteve, G. Garcia-Manero, U. Borate, 2021, Blood.

Letter: Primary aldosteronism: remission and development of adrenal insufficiency after adrenal venography.

E. Bravo, H. Taylor, C. Sachs, 1976, Annals of internal medicine.